AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Autor:	Harry P. Erba, Daniel A. Pollyea, Mikkael A. Sekeres, Guillermo Garcia-Manero, Karen Seiter, Irene S. DeGutis, Pavel Kiselev, Ali McBride, Edward Yu, Gail J. Roboz
Rok vydání:	2022
Předmět:	Cancer Research Oncology Hematology
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 22:S229-S230
ISSN:	2152-2650
DOI:	10.1016/s2152-2650(22)01254-x
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::84f6414c0420efe9a497f2b0b295f1c8 https://doi.org/10.1016/s2152-2650(22)01254-x Zobrazit plný text záznamu Full Text from ScienceDirect